Drug intelligence / Profile preview

Virulina

Development stage: Preclinical
Lead developer: Natural Solutions and Nutraceuticals
Administration: Oral

Overview

Virulina is a polyherbal formulation developed by Natural Solutions Neutech Pvt Ltd for the treatment of COVID-19, viral infections, and Acute Respiratory Distress Syndrome (ARDS). The formulation is claimed to possess potent antiviral activity by inhibiting the RNA-directed RNA polymerase (RdRp), an enzyme essential for the replication of RNA viruses. According to the developer, Virulina demonstrated 95.9% inhibition of the SARS-CoV-2 Wuhan strain in laboratory studies. It is designed to reduce viral load and mitigate the inflammatory response associated with severe respiratory distress, providing a natural therapeutic approach to managing viral outbreaks.

Brand names: Virulina
Other names: Virulina-S

Targets

RdRp (Coronavirus RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on Virulina.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virulina.

Explore the full profile